Journal
SCIENCE ADVANCES
Volume 7, Issue 41, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abj5435
Keywords
-
Categories
Funding
- European Union's Horizon 2020 research and innovation program [680242-ERC]
- Israel Innovation Authority [67967]
- Israel Science Foundation [1778/13, 1421/17]
- Israel Ministry of Economy [52752, 69230]
- Israel Ministry of Science Technology and Space-Office of the Chief Scientist [3-11878]
- Israel Ministry of Science, Technology and Space [3-16963, 3-17418]
- Israel Cancer Association [2015-0116]
- Leventhal 2020 COVID19 Research Fund [11947]
- German-Israeli Foundation for Scientific Research and Development [I-2328-1139.10/2012]
- European Union FP-7 IRG Program for a Career Integration Grant [908049]
- Phospholipid Research Center Grant [ASC-2018-062/1-1]
- Ministry of Agriculture and Rural Development-Office of the Chief Scientist [323/19]
- Louis family Cancer Research Fund
- Mallat Family Foundation
- Unger Family Fund
- Carrie Rosenblatt Cancer Research Fund
- Technion Integrated Cancer Center (TICC)
- Russell Berrie Nanotechnology Institute
- Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering
- Alon and Taub Fellowships
- TEVA Pharmaceuticals The National Forum for Bio-Innovators (NFBI)
- Technion Integrated Cancer Center (TICC) Rubinstein scholarship
- Robert B. Kalmansohn Fellowship Fund
- Israeli Ministry of Science and Technology
- Basque Country Government
- European Research Council (ERC) [680242] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Neurons within the tumor microenvironment play a role in promoting cancer progression, making local targeting of neurons potentially beneficial in clinical applications. Utilizing PEGylated lipid nanoparticles loaded with bupivacaine, researchers were able to suppress nerve-to-cancer cross-talk and inhibit cancer cell viability by curbing neurite growth and signaling in breast cancer tumors. The findings suggest that reducing nerve involvement in tumors is crucial for effective cancer treatment.
Neurons within the tumor microenvironment promote cancer progression; thus, their local targeting has potential clinical benefits. We designed PEGylated lipid nanoparticles loaded with a non-opioid analgesic, bupivacaine, to target neurons within breast cancer tumors and suppress nerve-to-cancer cross-talk. In vitro, 100-nm nanoparticles were taken up readily by primary neurons, trafficking from the neuronal body and along the axons. We demonstrate that signaling between triple-negative breast cancer cells (4T1) and neurons involves secretion of cytokines stimulating neurite outgrowth. Reciprocally, neurons stimulated 4T1 proliferation, migration, and survival through secretion of neurotransmitters. Bupivacaine curbs neurite growth and signaling with cancer cells, inhibiting cancer cell viability. In vivo, bupivacaine-loaded nanoparticles intravenously administered suppressed neurons in orthotopic triple-negative breast cancer tumors, inhibiting tumor growth and metastatic dissemination. Overall, our findings suggest that reducing nerve involvement in tumors is important for treating cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available